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Abstract
Background:  We have used a mouse model based on overexpression of c-Myc  in B cells
genetically engineered to be self-reactive to test the hypothesis that farnesyl transferase inhibitors
(FTIs) can effectively treat mature B cell lymphomas. FTIs are undergoing clinical trials to treat both
lymphoid and non-lymphoid malignancies and we wished to obtain evidence to support the
inclusion of B cell lymphomas in future trials.
Results: We report that two FTIs, L-744,832 and SCH66336, blocked the growth of mature B cell
lymphoma cells in vitro and in vivo. The FTI treatment affected the proliferation and survival of the
transformed B cells to a greater extent than naïve B cells stimulated with antigen. In syngeneic mice
transplanted with the transgenic lymphoma cells, L-744,832 treatment prevented the growth of the
tumor cells and the morbidity associated with the resulting lymphoma progression. Tumors that
arose from transplantation of the lymphoma cells regressed with as little as three days of treatment
with L-744,832 or SCH66336. Treatment of these established lymphomas with L-744,832 for seven
days led to long-term remission of the disease in approximately 25% of animals.
Conclusion: FTI treatment can block the proliferation and survival of self-reactive transformed B
cells that overexpress Myc. In mice transplanted with mature B cell lymphomas, we found that FTI
treatment led to regression of disease. FTIs warrant further consideration as therapeutic agents for
mature B cell lymphomas and other lymphoid tumors.
Background
We have tested farnesyl transferase inhibitors (FTIs) using
a mouse model of mature B cell lymphoma to determine
if these drugs may be useful in treating similar lymphoid
cancers. Although FTIs were originally developed to block
the activation of the Ras family of oncogenes, they are also
effective in blocking the growth of tumor cells that do not
contain mutations at any of the Ras alleles [1]. By blocking
the normal processing and subcellular targeting of most
farnesylated proteins in the cell, FTI treatment can have
many effects. This is due to the large number of far-
nesylated proteins present, including proteins of the Rho
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family that are known to mediate antigen receptor signal-
ing in B cells. We therefore chose to test the efficacy of FTIs
against our murine B cell lymphoma model, even though
there is presently no evidence that activation of Ras plays
a role in genesis of the tumors.
The two FTIs that we tested are L-744,832 and SCH66336
(Sarasar, lonafarnib). Developed by Merck, L-744,832 is a
peptidomimetic competitive inhibitor of farnesyl trans-
ferase that blocks the binding of CAAX peptide substrates.
L-744,832 has been shown to block the growth of a vari-
ety of tumor cell lines in vitro [2-4], nude mouse
xenografts of human tumor cell lines [5], and mouse
tumor models [6-11]. SCH66336 was developed by Scher-
ing Plough, completed Phase I clinical trials [12-14], and
is currently in Phase II [15] and Phase III clinical trials. In
vitro, SCH66336 has been shown to cause cell death in
tumor cell lines [16-18]. Preclinical studies demonstrated
that SCH66336 is orally bioavailable and could block the
growth of human tumor cells in mouse xenografts [19]
and of mouse tumor cells in transgenic models [17,19-
21]. The efficacy of L-744,832 and SCH66336 does not
appear to correlate with the expression of activated Ras
protein in either human or murine tumors. Although
these two FTIs have been tested in other preclinical mod-
els [22], the efficacy of this class of drugs has not been
examined in clinical trials with B cell lymphoma patients.
Certain lymphoid malignancies are sensitive to FTI treat-
ment [23], suggesting that FTIs can affect the proliferation
or survival signaling pathways in lymphocytes. The
growth of large cleaved cell lymphomas in transgenic
mice expressing an N-Ras oncogene driven by the MMTV
promoter can be prevented by SCH66336 treatment [8].
Transformed lymphocytes from T cell ALL patients acti-
vate cell death when treated with the FTI R115777 in vitro
[24]. In addition to their effects on cancer cells, FTIs have
also been shown to affect normal lymphocyte signaling. T
cell proliferation stimulated by antigen receptor activa-
tion can be blocked by the FTIs cinnamaldehyde [25] and
A-228839 [26]. The dual prenylation inhibitor, L-
778,123, which blocks both farnesylation and geranylger-
anylation, blocks T cell proliferation activated either by
antigen receptor-stimulation or by interleukin-2 (IL-2),
without affecting IL-2-mediated survival [27]. Statins,
which indirectly affect farnesylation and geranylgeranyla-
tion through mevalonate biosynthesis, are also known to
have immunomodulatory effects [28].
We have used a mouse model in which the overexpression
of the proto-oncogene c-Myc creates a breach of tolerance
in B cells [29]. The self-reactive B cells in these mice gen-
erate a mature B cell lymphoma that closely resembles
Burkitt's lymphoma in humans [30]. The mice express
three transgenes: (A) the oncogene c-Myc expressed from
the Eμ immunoglobulin (Ig) heavy chain promoter, (B)
the pre-rearranged Ig heavy and light chains specific for
hen egg lysozyme (HEL) expressed from the endogenous
Ig promoter, and (C) secreted HEL expressed from a met-
allothionine promoter. The majority of B cells in the Eμ-
Myc/BCRHEL/HEL transgenic mice express only BCRHEL
IgM on their surface and are specific for the self-antigen,
HEL. Tolerance to this self-antigen is overcome by the
over-expression of c-Myc in these cells [29] and the result-
ing autoreactive B cells are hyperproliferative and form
tumors in the lymph nodes and spleen. The lymphoma
phenotype occurs in 100% of the Eμ-Myc/BCRHEL/HEL
transgenic mice with a median latency of 8 weeks [30].
The tumors can be transplanted into unmanipulated
C57BL/6 mice and the transplant recipients uniformly
develop tumors after 3–4 weeks that appear identical to
those in the transgenic donors. This transgenic mouse line
is similar to other lymphoma models that overexpress c-
Myc [31-34], except for context of overexpression, in auto-
reactive B cells. Antigen receptor activation may be simi-
larly involved in tumorigenesis in certain human
lymphoid malignancies [35].
The development of the Eμ-Myc/BCRHEL/HEL mice per-
mits preclinical testing in this model in an effort to ascer-
tain whether clinical trials of FTIs on mature B cell
lymphomas, such as Burkitt's lymphoma, might be in
order. In this report, we have demonstrated that FTIs can
disrupt the growth and survival pathways in the murine
tumor cells. Mice with transplanted tumors showed
responses to either FTI, demonstrating effectiveness in vivo
of this class of drug against this malignant B cell lym-
phoma. These preclinical results may have important
implications for the treatment of B cell lymphomas in
humans, particularly those whose proliferation or survival
are dependent on antigen activation.
Results
Mouse B cell lymphoma cells are sensitive to L-744,832 in 
vitro
In order to evaluate whether the murine mature B cell
lymphoma might respond to FTIs, we measured prolifer-
ation of tumor cells in vitro. The tumor B cells from Eμ-
Myc/BCRHEL/HEL transgenic mice proliferated in the
absence of exogenous stimulation (Figure 1, panel f). In
contrast, naïve B cells from mice carrying only the BCRHEL
transgene did not proliferate without stimulation (Figure
1, panel a), but showed several rounds of cell division
when stimulated with a mixture of anti-IgM and anti-
CD40 (Figure 1, panel b). The growth of the murine tumor
cells in culture provided the opportunity to test the effi-
cacy of experimental compounds such as FTIs.
Proliferation of the mouse lymphoma cells can be
blocked by the FTI, L-744,832. At relatively low concentra-Molecular Cancer 2008, 7:39 http://www.molecular-cancer.com/content/7/1/39
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tions of this drug (0.4 μM, Figure 1, panels c and h), there
was no antiproliferative effect on either nontransformed
or tumor B cells. At 4 μM L-744,832, a slight effect was
seen on the nontransformed B cells (Figure 1, panel d),
but the proliferation of the tumor cells was almost com-
pletely blocked (Figure 1, panel i). At a concentration of L-
744,832 that was not likely to be pharmacologically rele-
vant (40 μM, panels e and j), the proliferation of both cell
Proliferation of mouse lymphocytes and lymphoma cells in vitro in the presence and absence of L-744,832 Figure 1
Proliferation of mouse lymphocytes and lymphoma cells in vitro in the presence and absence of L-744,832. 
Splenocytes were harvested from either a BCRHEL transgenic mouse (panels a-e) or a moribund Eμ-Myc/BCRHEL/HEL transgenic 
mouse (panels f-j). The splenocytes were depleted of T cells and labeled with CFSE. Cells were cultured in RPMI (panels a, f-j) 
or RPMI with 2 μg/ml anti-IgM and 1 μg/ml anti-CD40 (panels b-e) and 0 – 40 μM L-744,832 were included in the culture media, 
as indicated. After three days, cellular proliferation was measured by flow cytometry. Cells that have proliferated measure less 
than 103 fluorescence units. For comparison, panels c, d, and e show proliferation in the absence of L-744,832 as a black line.Molecular Cancer 2008, 7:39 http://www.molecular-cancer.com/content/7/1/39
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types was almost completely blocked. From these data, we
concluded that L-744,832 prevented the proliferation of
the mouse lymphoma cells in vitro and that, under these
conditions, it had a greater effect on the tumor cells than
on the proliferation of activated, non-transformed B cells
stimulated by antigen receptor and CD40 activation.
Efficacy of L-744,832 in vivo
We next utilized our ability to transplant the murine B cell
lymphoma into syngeneic mice to test the efficacy of FTIs
in the mouse model. For four separate experiments, lym-
phoma cells were freshly isolated from the lymph nodes
and spleen of an Eμ-Myc/BCRHEL/HEL transgenic mouse
and 106 cells were transplanted into each of a cohort of
C57BL/6 recipients. Figure 2A shows, for one of the exper-
iments, the number of spleen cells isolated from mice that
were transplanted with 106 tumor cells 28 days earlier or
C57BL/6 mice that had not received tumor cells. Flow
cytometry confirmed that the additional cells in the
spleen were activated B cells (B220+ and CD69+) that
express BCRHEL (IgMa) on their surface (data not shown).
These observations indicate that the transplanted cells
have formed lymphomas in the recipient mice.
In this experiment, four mice in each group were treated
once daily with 625 μg of L-744,832 (~40 mg/kg) intrave-
nously starting the day after tumor transplantation and
four mice were left untreated. Daily administration of L-
744,832 prevented the transplanted tumors from causing
splenomegaly in recipient mice (Figure 2A). Treatment of
the wild-type mice also resulted in a small, but significant,
decrease in the number of isolated splenocytes and the
numbers of viable cells isolated are similar for the two
groups of FTI-treated mice.
Figures 2B and 2C show the results from a separate exper-
iment where the recipients were not treated immediately
after transplantation of the tumor. Transplant recipients
either were treated for 7 days beginning 21 days after
transplantation (L744 × 7), when enlarged lymph nodes
were visible upon external examination, or were treated
for 3 days beginning 24 days after transplantation (L744
× 3), when the mice were beginning to show debilitation
due to the lymphomas. The mice were then treated with L-
744,832 as above, or left untreated, for comparison. The
administration of L-744,832 for either 7 or 3 days caused
a large reduction in the size of the spleen (Figure 2B), as
well as the lymph nodes and thymi (data not shown) and
a corresponding drop in the number of cells isolated from
the spleen (Figure 2C). The treated mice became more
active and resumed grooming behavior within two days of
the start of treatment. Similar results were observed in all
four experiments using L-744,832. Together, these experi-
ments show that L-744,832 can prevent mature B cell lym-
Treatment of lymphoma-bearing mice with L-744,832 Figure 2
Treatment of lymphoma-bearing mice with L-744,832. A. L-744,832 treat-
ment prevents the B cell lymphoma from becoming established. Unmanipulated 
C57BL/6 mice (Wild-type) or mice transplanted with 106 Eμ-Myc/BCRHEL/HEL trans-
genic lymphoma cells (Transplant recipient) were injected intravenously with 625 μg 
L-744,832 in 0.25 ml PBS daily (light bars) or left untreated (black bars). After 28 
days, mice were euthanized and the spleens were dissected and viable cell counts of 
splenocytes resuspended in RPMI were determined using a hemocytometer. Error 
bars represent the standard deviation calculated for all mice in each group (n = 4). B 
and C. L-744,832 treatment causes rapid regression of lymphomas. In a separate 
experiment, mice transplanted with transgenic tumor cells were allowed to develop 
tumors for 20 or 24 days before daily treatment with L-744,832 as above for either 7 
days (L744 × 7) or 3 days (L744 × 3), respectively. Twenty eight days following the 
tumor transplantation the mice were euthanized. Spleens were removed from tumor 
recipient mice and C57BL/6 control mice and photographed. Single cell suspensions 
from the spleens of mice that were left untreated (black bars), treated for the final 7 
days (shaded bars), or treated for the final 3 days (clear bars) were counted using a 
hemocytometer. Data shown are the average of 4 mice in each group and error bars 
represent the standard deviation.Molecular Cancer 2008, 7:39 http://www.molecular-cancer.com/content/7/1/39
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phomas from becoming established in mice and can
cause established tumors to regress.
Efficacy of SCH66336 in vivo
We wanted to see if a distinct FTI, SCH66336, could have
similar effects on the B cell lymphoma model. In three
separate experiments, which all yielded similar results, we
transplanted 106 transgenic tumor cells into a cohort of
C57BL/6 recipients. Approximately 2 weeks after trans-
plantation, some of the mice were treated by oral gavage
with 1.56 mg SCH66336 (~100 mg/kg) or with vehicle
every 12 hours. After 3 days of treatment, the mice were
euthanized and splenocytes were isolated for analysis.
Mice that were not treated with FTI showed an average 10-
fold increase in the number of splenocytes isolated, indi-
cating growth of the lymphoma from the cells trans-
planted 18 days earlier (Figure 3). Mice treated for 3 days
with SCH66336 showed a large decrease in the number of
isolated splenocytes, resulting in numbers equal to unma-
nipulated C57BL/6 mice. Tumor recipient mice that were
treated with a vehicle control instead of SCH66336 actu-
ally showed a slight decrease in the number of spleno-
cytes, although this was not consistently seen in other
experiments. During SCH66336 treatment both tumor
recipient and untransplanted mice were adversely affected
by the drug, as demonstrated by weight loss and lack of
activity. Because of these effects, we were unable to extend
the treatment at this dosage past 3 days.
Flow cytometry analysis of lymphocytes from FTI-treated 
mice
Flow cytometry was used to more closely examine the
effects of FTI treatment on the tumor cells and normal
lymphocytes. In Figure 4A, cells from the lymph nodes,
spleen, or thymus of wild-type mice were fluorescently
stained with antibodies to Thy1.2 and B220 to identify T
cells and B cells, respectively. Comparison of untreated
mice (top panels) to mice treated for 28 days with L-
744,832 (bottom panels) demonstrates that there were no
significant differences in the relative numbers of B cells or
T cells in the lymph nodes (untreated mice: 23.3 ± 0.6% B
cells, 69.5 ± 1.3% T cells; treated mice: 36.3 ± 5.8% B cells,
56.5 ± 5.9% T cells) and spleen (untreated mice: 51.1 ±
3.8% B cells, 34.9 ± 3.5% T cells; treated mice: 52.5 ±
2.8% B cells, 33.3 ± 1.6% T cells). It did not appear that
prolonged FTI treatment had substantially affected the
normal distribution of lymphocytes in these organs.
Mice that received tumor transplants 28 days prior to
analysis (Figure 4B, top panels) had a large increase in the
number of B cells in all three lymphoid organs (lymph
nodes 62.4 ± 26.1%, spleen 57.7 ± 6.9%, thymus 71.8 ±
6.5%). The presence of the tumor cells was accompanied
by a large increase in the size of the affected organs (Figure
2 and data not shown). However, a small percentage of T
cells remained and the total number of T cells in each
organ did not decrease appreciably (Table 1). Treatment
of the tumor recipient mice with L-744,832 for either 28
days (Figure 4B middle panels) or for the last 7 days (Fig-
ure 4B bottom panels) results in flow cytometry profiles
that appeared much more similar to those from wild-type
mice. The relative numbers of B cells and T cells in the
lymph nodes (28-day treatment: 29.4 ± 2.7% B cells, 63.1
± 1.8% T cells; 7-day treatment: 31.1 ± 0.8% B cells, 61.1
± 0.7% T cells) and spleen (28-day treatment: 52.6 ± 4.8%
B cells, 37.7 ± 4.8% T cells; 7-day treatment: 55.1 ± 2.4%
B cells, 33.8 ± 2.4% T cells) returned to nearly normal.
Careful comparison of the plots does reveal subtle differ-
ences, such as the presence of a significant number of B
cells with a lower amount of B220 in the peripheral lym-
phoid organs. A small, but significant, percentage of resid-
ual B220+/Thy1- cells remained in the thymus, even after
28 days of treatment. This appears to be due to a decrease
in the number of T cells in the thymus that accompanied
L-744,832 treatment (3.8 ± 1.9 × 107 T cells in untreated
mice compared to 9.2 ± 0.8 × 105 T cells in tumor-recipi-
ent mice treated with L-744,832 for 28 days). The absolute
number of T cells declined substantially in all of the lym-
Treatment of lymphoma-bearing mice with SCH66336 Figure 3
Treatment of lymphoma-bearing mice with 
SCH66336. SCH66336 treatment for 3 days causes B cell 
lymphomas to regress in mice. The numbers of viable, iso-
lated splenocytes are shown from unmanipulated C57BL/6 
mice (Wild-type) or mice transplanted 18 days earlier with 
106 lymphoma cells from an Eμ-Myc/BCRHEL/HEL transgenic 
mouse (Transplant Recipient). Mice were either left 
untreated (black bars), treated orally for the last 3 days with 
1.56 mg SCH66336 every 12 hours (shaded bars), or treated 
orally for the last 3 days with vehicle alone every 12 hours 
(clear bar). Each group contains 4 mice and error bars repre-
sent the standard deviation for each group.Molecular Cancer 2008, 7:39 http://www.molecular-cancer.com/content/7/1/39
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phoid organs of tumor-bearing mice that were treated
with L-744,832 (Table 1).
Analysis of residual tumor levels following FTI treatment
The transplanted lymphoma cells accumulate in the bone
marrow of recipient mice and we used this property to
quantify the amount of residual tumor left after L-744,832
treatment. We used the allotypic IgMa marker specific for
the BCRHEL transgene in donor tumor cells to distinguish
them from the IgMb-expressing B cells normally present in
C57BL/6 bone marrow. As illustrated in panel a of Figure
5, bone marrow from unmanipulated C57BL/6 mice did
Flow cytometry of isolated cells from mice treated with L-744,832 Figure 4
Flow cytometry of isolated cells from mice treated with L-744,832. Relative numbers of B- and T-cells were measured from unmanipulated 
C57BL/6 mice (A) or C57BL/6 mice that had received transgenic lymphoma transplants 28 days previously (B). The mice were left untreated or treated 
with L-744,832 for 28 days (L744 × 28) or for the final 7 days (L744 × 7). The numbers of B cells (upper left quadrant) and T cells (lower right quadrant) 
isolated from lymph nodes (first column), spleen (second column), or thymus (third column) were determined by flow cytometry after staining with anti-
bodies to B220 and Thy1.2. The mean percentage and standard deviation of the B220+ and the Thy1.2+ cells are shown in the appropriate quadrant of each 
plot. There were 4 mice in all groups, except the L744 × 28 wild-type group, which had 2 mice.Molecular Cancer 2008, 7:39 http://www.molecular-cancer.com/content/7/1/39
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not contain IgMa expressing cells. Bone marrow from mice
transplanted 28 days earlier with lymphoma cells con-
tained abundant tumor cells and an average of 51.9% of
the cells were positive for IgMa (Figure 5, panel b). The
effects of L-744,832 treatment for either 28 or 7 days can
be seen in Figure 5, panels c and d, respectively; the IgMa-
expressing tumor cells in the bone marrow were signifi-
cantly reduced (p < 0.01). Even after 28 days of treatment
a small, but substantial number of the transgenic B cells
remained when compared to mice that did not receive a
transplant (p = 0.04).
Similar results were seen when SCH66336 was used to
treat mice transplanted with mature B cell lymphomas.
When we examined isolated splenocytes for expression of
IgMa and B220 as markers for the lymphoma cells from
the tumor transplant (Figure 6), we found that about 32%
of the cells were positive for these two markers 18 days
after transplantation. Treatment with SCH66336 for 3
days led to a statistically significant decrease (p < 0.05) in
the number of tumor cells to 5% of splenocytes, although
they were not completely eliminated.
Sustained remissions of B cell lymphomas with brief L-
744,832 treatment
We next examined whether the treatment of tumor-bear-
ing mice for 7 days with L-744,832 could cause long-last-
ing remissions from acute B cell lymphoma. Two separate
experiments were conducted with either 5 mice (Figure
7A) or 10 mice (Figure 7B) that had received 106 tumor
cells and were then treated with L-744,832 for 7 days,
starting 21 days after the transplantation, when lympho-
mas were first evident by external examination in all trans-
plant recipient mice. In the first experiment, the untreated
mice became moribund and were euthanized between 5
and 6 weeks after transplantation. One of the treated mice
did not appear to respond to L-744,832 treatment and
tumor progression was similar to untreated mice. Three of
the remaining 4 treated mice showed temporary remis-
sions of lymphoma. There were no signs of lymphaden-
opathy in these mice until approximately 6 weeks after the
treatment ended. These 3 mice survived for approximately
17 weeks and developed very large, indolent lymphomas
that were not as aggressive as the original transplanted
cells, which would be expected to cause morbidity within
3 weeks of visible lymphadenopathy. Lymphadenopathy
never returned in the fifth treated mouse and it was euth-
anized after 52 weeks. Necropsy showed no signs of
splenomegaly or lymphadenopathy (data not shown).
In the second experiment (Figure 7B), the untreated
tumor recipients showed visible signs of tumor at 3 weeks
and had to be euthanized between 3 and 6 weeks. Ten
other tumor recipient mice were treated with L-744,832
starting 21 days after transplantation and 5 of these mice
died during treatment, apparently as a result of the treat-
ment. FTI treatment in these 5 mice caused their condition
to worsen rapidly and death typically occurred within an
hour of the first or second drug administration. Similar
acute reactions to FTI treatment were observed in other
mice with large tumors (data not shown). These adverse
reactions were not as severe in mice that did not receive
tumor transplants or in mice that were treated before large
tumors were present. This observation is consistent with
L-744,832 treatment causing tumor lysis syndrome in
mice with a large tumor burden, similar to what is seen in
human Burkitt's lymphoma patients treated with current
chemotherapy treatment [36]. Tumor lysis syndrome is
typically managed effectively in at-risk B cell lymphoma
patients [37]. Of the remaining 5 mice, 3 had temporary
remissions and later developed large lymphomas, becom-
ing moribund between 8 and 15 weeks after treatment.
The lymphadenopathy did not return in the remaining 2
treated mice and they remained healthy 26 weeks after
Table 1: Absolute number of viable B cells and T cells after L-744,832 treatment
Lymph Nodes Spleen Thymus
Untreated Wild-type B: 8.3 ± 4.4 × 105 B: 3.8 ± 0.8 × 107 B: 4.0 ± 3.2 × 105
T: 2.5 ± 1.2 × 106 T: 2.5 ± 0.2 × 107 T: 3.8 ± 1.9 × 107
L744 × 28 Wild-type B: 9.9 ± 2.8 × 105 B: 1.4 ± 0.8 × 107 B: 1.3 ± 0.6 × 105
T: 1.6 ± 0.9 × 106 T: 9.0 ± 0.5 × 106 T: 1.8 ± 0.7 × 107
Untreated Transplant B: 2.0 ± 2.5 × 107 B: 1.8 ± 1.0 × 108 B: 7.4 ± 5.9 × 107
T: 4.2 ± 3.9 × 106 T: 4.0 ± 5.4 × 107 T: 2.3 ± 2.1 × 107
L744 × 28 Transplant B: 2.3 ± 0.8 × 105 B: 7.6 ± 2.9 × 106 B: 9.4 ± 6.6 × 104
T: 4.8 ± 1.3 × 105 T: 5.6 ± 2.4 × 106 T: 9.2 ± 0.8 × 105
L744 × 7 Transplant B: 2.9 ± 0.7 × 105 B: 1.0 ± 0.4 × 107 B: 5.9 ± 1.9 × 105
T: 5.7 ± 1.2 × 105 T: 6.5 ± 3.2 × 106 T: 9.2 ± 1.9 × 105
The number of viable B cells and T cells is shown for cells isolated from either the lymph nodes, spleen, or thymus of mice. The mice are either 
C57BL/6 (Wild-type) or C57BL/6 transplanted with tumor cells from transgenic mice 28 days earlier (Transplant). The mice were left untreated or 
treated with L-744,832 for 28 days (L744 × 28) or for the final 7 days (L744 × 7). Total cell number was measured with a Coulter Counter, 
corrected for cell viability by 7AAD staining, and then multiplied by the relative number of B or T cells determined by B220 or Thy-1 staining, 
respectively. Data are from the same experiment as shown in Figure 4.Molecular Cancer 2008, 7:39 http://www.molecular-cancer.com/content/7/1/39
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treatment when they were euthanized, showing no evi-
dence of splenomegaly or lymphadenopathy. From these
two experiments, combined, we found that 40% (6/15) of
the mice died as a possible effect of L-744,832 treatment,
and of the mice that survived initial treatment, 33% (3/9)
showed long term recovery with no evidence of lym-
phoma.
Discussion
Selectivity of FTIs for tumor cells
In the mouse lymphoma model used here, two signaling
pathways have been manipulated to generate tumor B
cells that recognize a self antigen. Continuous antigen
receptor stimulation, provided by the co-expression of
BCRHEL and HEL, drives B cell proliferation. This would
normally lead to cell death or B cell anergy [38]; however,
the over-expression of c-Myc in these autoreactive B cells
overcomes tolerance, allowing the tumor cells to survive
and hyperproliferate [29]. The cooperation of c-Myc over-
expression and antigen receptor signaling in tumorigene-
sis may be related to the observation that the Myc tran-
scription factor is required for cytokine-dependent
survival signaling in lymphocytes [29]. Over-expression of
c-Myc in transgenic B cells renders them independent of
cytokines for proliferation and survival in vitro [29]. We
reasoned that one or more farnesylated proteins were
likely to be critical for the antigen receptor or cytokine
receptor/Myc signaling pathways. Therefore, inhibition of
farnesyl transferase might restore normal regulation to the
dysplastic B cells. Our results clearly support this hypoth-
esis and strongly implicate at least one farnesylated pro-
tein in either of these two signaling pathways. This result,
Tumor cells decrease in SCH66336-treated mice Figure 6
Tumor cells decrease in SCH66336-treated mice. 
Splenocytes were isolated and stained with antibodies to 
IgMa and B220 to detect the transgenic lymphoma cells. The 
percent of viable splenocytes positive for both markers is 
shown for unmanipulated C57BL/6 mice (Wild-type) or mice 
transplanted with 106 tumor cells 18 days earlier (Transplant 
recipient). Results from untreated mice are shown with black 
bars and from transplant-recipient mice treated with 1.56 mg 
SCH66336 by oral gavage twice daily for 3 days with shaded 
bars. The average and standard deviation for 4 mice in each 
group is shown.
Tumor presence in bone marrow is blocked by L-744,832 Figure 5
Tumor presence in bone marrow is blocked by L-
744,832. The presence of IgMa positive transgenic lymphoma 
cells in the bone marrow was measured using flow cytome-
try. C57BL/6 mice were transplanted with 106 tumor cells 
from an Eμ-Myc/BCRHEL/HEL mouse (panels b-d) or left 
unmanipulated (panel a). Transplant recipient mice were left 
untreated (panel b) or treated with L-744,832 for either 28 
days (panel c) or for the final 7 days of the experiment (panel 
d). Bone marrow was harvested from the femurs and tibias of 
wild-type mice (panel a), untreated tumor recipient mice 
(panel b), 28-day treated tumor recipient mice (panel c) or 7-
day treated tumor recipient mice (panel d). Isolated cells 
were stained for IgMa and analyzed by flow cytometry. The 
mean percentage and standard deviation of IgMa positive cells 
are indicated above each histogram for 4 mice in each treat-
ment group.Molecular Cancer 2008, 7:39 http://www.molecular-cancer.com/content/7/1/39
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alone, is hardly surprising, but what we find most interest-
ing is the apparent specificity of the FTI for the tumor B
cells compared to nontransformed lymphocytes. When
the proliferation of activated B cells and the transformed
B cells were compared in vitro, the tumor cells were
approximately 10-fold more sensitive to L-744,832 treat-
ment than naïve B lymphocytes stimulated with antigen
receptor and CD40 antibodies (Figure 1).
Similar selectivity for tumor cells was observed in vivo. FTI
treatment of mice for as little as three days eliminated >
90% of the tumor cells, while only slightly affecting the
normal lymphocyte populations in the same mice (Fig-
ures 2, 3, and 4). When mice without tumors were treated
with L-744,832 for as long as 28 days, no significant
changes were seen in the development of cells in the lym-
phoid lineages (Figure 4), a process that involves antigen
receptor signaling during positive and negative selection
of immature lymphocytes. This suggests that the tumor B
cells are more susceptible to loss of the functional targets
of FTIs than normal B cells. There are at least two explana-
tions for the greater sensitivity of the transformed cells.
FTIs could suppress lymphocyte activation specifically
under conditions of very high antigenic stimulation, as in
the case of a self-antigen, or the breach of tolerance by c-
Myc over-expression could render the B cells sensitive to
the FTI. These possibilities have implications for the pos-
sible use of FTIs to treat autoimmune disease or in condi-
tions of alloreactivity.
Further investigation will be necessary to identify the
mechanism that FTIs may be affecting in order to exert the
biological effects that we observe. Farnesyl transferase is
estimated to modify 40 to 50 different proteins in mam-
malian cells and the critical anti-neoplastic targets of FTI
treatment remain unknown [1,39]. Proteins whose inhi-
bition can mediate anti-cancer effects of FTIs include
RhoB [40] and the centromeric proteins CENP-E and
CENP-F [41]; most likely a combinatorial effect on many
farnesylated proteins is necessary for the cytostatic and
cytotoxic effects of FTIs [42].
The demonstration that several different FTIs can block
the production of TH1 and TH2 cytokines from T cells in
culture [43] may provide a partial explanation for the
effects of these drugs in our experiments. Marks et al. dem-
onstrate that FTI treatment of activated T cell clones
blocked the secretion of IL-2, interferon-γ, IL-4, and IL-5.
Cytokine signaling plays a critical role in lymphocyte pro-
liferation and survival, as well as establishing tolerance to
self antigens [44]. Therefore, it is possible that FTI treat-
ment affects the hyperproliferation of the self-reactive B
cells by interfering with cytokine production. However,
the overexpression of Myc in the self-reactive B cells stud-
ied here presumably substitutes for IL-4 receptor activa-
tion and the transgenic B cells do not require IL-4
production for survival and proliferation [43]. Therefore,
we view it as unlikely that the Myc-overexpressing B cells
would be affected by an FTI-dependent block of IL-4 pro-
duction. However, FTI treatment may decrease the pro-
duction of cytokines by the transformed B cells, which
may, in turn, affect the regulatory environment surround-
ing the B cells and help to restore self tolerance to the HEL
self antigen.
Comparison to other FTI preclinical studies
FTI treatment has been shown to have anti-tumor activity
in several other mouse cancer models. The mature B cell
lymphoma studied here is similar to the non-Hodgkin
lymphoma studied by R. Mangues, et al., who demon-
Long-term remission and regression of lymphomas after L- 744,832 treatment Figure 7
Long-term remission and regression of lymphomas 
after L-744,832 treatment. In two separate experiments 
(panels A and B) mice transplanted with transgenic lym-
phoma cells were treated for 7 days with L-744,832 starting 
21 days after transplantation (blue line) or left untreated (red 
line). In the first experiment (panel A), 5 mice each were 
treated with L-744,832 or left untreated. In the second 
experiment (panel B), 10 mice were treated with L-744,832 
and 5 mice were untreated. Mice were then monitored for 
signs of lymphadenopathy and euthanized when moribund.Molecular Cancer 2008, 7:39 http://www.molecular-cancer.com/content/7/1/39
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strated that L-744,832 could prevent the formation of dif-
fuse large B cell splenic lymphomas in mice that expressed
an activated N-Ras oncogene under the MMTV promoter
[8]. L-744,832 has also been shown to cause regression of
mammary and salivary tumors in mice expressing MMTV-
v-H-Ras alone [45], or together with MMTV- c-Myc [7].
Unlike the above transgenic tumor models, the murine
lymphoma studied here does not contain an activated Ras
transgene but may express a spontaneously activated Ras
allele. Such mutations are not commonly found in B cell
non-Hodgkin lymphomas in humans [46], however, we
cannot rule out that a spontaneous mutation occurred at
one of the Ras alleles during the process of tumorigenesis
in our mouse model. FTIs have mixed results with other
mouse tumors that are not known to harbor Ras muta-
tions. For example, the mammary tumors in MMTV- c-
Neu mice do not respond to L-744,832 [7], but the pre-B-
cell leukemia in BCR/Abl transgenic mice regressed upon
treatment with SCH66336 [21]. Our results are consistent
with other models that do not use Ras mutations as an ini-
tiating tumorigenic event but have shown that FTI treat-
ment can still effectively block tumor growth.
Implications for treatment of human B cell lymphomas
Our preclinical results with this mouse lymphoma model
indicate that patients with mature B cell lymphomas
should be considered for inclusion in FTI clinical trials.
One of the important features of this mouse model is the
self-reactivity of the transformed B cells. Although FTIs do
not appear to block proliferation of nontransformed B
cells in response to antigen receptor stimulation, these
drugs were able to block proliferation and induce cell
death in the self-reactive transformed B cells. Antigen
receptor activation by self or environmental antigens may
contribute the generation of certain B cell malignancies in
humans [35]. Recognition of autoantigens or foreign anti-
gens from a chronic infection appears to be an important
feature of a substantial fraction of B cell chronic lym-
phocytic leukemias [47,48], follicular lymphomas [49],
and certain other leukemias and lymphomas [35]. We
suggest that FTIs may be able to block the proliferation of
BCR-expressing B cell lymphomas by interfering with the
antigen receptor and/or cytokine signaling pathways
within the transformed cells.
The lymphoma in the mice used in this study most closely
resembles Burkitt's lymphoma, and we propose that FTIs
might be a useful addition to the chemotherapy for this
cancer. The Raji Burkitt's lymphoma cell line has been
shown to be sensitive to a geranylgeranyl transferase
inhibitor and to lovastatin but less sensitive to an FTI [50].
Together with our results, this suggests that both FTIs and
geranylgeranyl transferase inhibitors should be investi-
gated as possible Burkitt's lymphoma treatments. Initial
clinical trials using FTIs focused on cancers that were
likely to harbor activating Ras mutations, such as pancre-
atic cancer. However, subsequent experience has led to the
inclusion of many additional patient groups in FTI clini-
cal trials. For example, SCH66336 is undergoing a phase
III clinical trial on myelodysplastic syndrome and chronic
myelomonocytic leukemia (Study ID P02978). However,
mature B cell lymphomas, such as Burkitt's, are not specif-
ically targeted in any of the current FTI clinical trials, per-
haps because of the high success rate of current therapies
for Burkitt's lymphoma.
Treatment of Burkitt's lymphoma typically involves a
combination of chemotherapies: cyclophosphamide,
etoposide, vincristine, bleomycin, doxorubicin, meth-
otrexate, and prednisone [36,51]. Recent evidence has
emerged that the anti-CD20 antibody Rituximab may
increase the efficacy of treatment in Burkitt's lymphoma,
as it does for other mature B cell lymphomas that express
CD20 [52]. Although the aggressive combination therapy
leads to long-term remission in most patients, at least
20% will relapse within five years and many patients are
not able to complete this regimen due to severe side
effects. In addition, success rates are considerably lower in
older adults and in developing countries where Burkitt's
lymphoma is most common [36]. The addition of an FTI
to this treatment, possibly in combination with Rituxi-
mab, could increase the success rate, allow comparable
success with less toxic chemotherapies, or allow more
effective treatment of relapsing or refractory cases. Impor-
tantly, in regions of the world where Burkitt's lymphoma
is most common, conventional treatments are less suc-
cessful and an orally effective FTI could, in combination
with other treatment, have a positive effect on the out-
come of this disease.
Conclusion
Using an Eμ-Myc/BCRHEL/HEL transgenic mouse model of
a mature B cell lymphoma, we found that FTI treatment
could block the hyperproliferation and survival of this
lymphoma in vitro and in vivo. Specifically, we showed
that proliferation in culture of the transformed B cells
from the transgenic mice was more sensitive to L-744,832
treatment than nontransformed activated B cells. In mice
we showed that either L-744,832 or SCH66336 treatment
caused a rapid loss of tumor cells transplanted from a
transgenic mouse. Treatment with L-744,832 for seven
days resulted in long term remissions from disease in one
third of mice that survived treatment. These results suggest
that FTIs should be considered as adjuncts for combina-
tion therapies or treatments for refractory cases in patients
with mature B cell lymphomas, including Burkitt's lym-
phoma and other lymphomas that may be dependent on
antigen receptor activation. It would be particularly inter-
esting to see if FTI treatment would be effective whenMolecular Cancer 2008, 7:39 http://www.molecular-cancer.com/content/7/1/39
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combined with Rituximab, an anti-CD20 antibody that
can be very effective at treating certain B cell lymphomas.
Methods
Mice
Eμ-Myc/BCRHEL/HEL transgenic mice have been previ-
ously described [29]. Eμ-Myc transgenic mice that overex-
press  c-Myc  in B cells after the Pre/Pro-B cell stage of
development [53] were obtained from The Jackson Labo-
ratory (Bar Harbor, ME). BCRHEL transgenic mice that
expressed a pre-rearranged, HEL-specific B cell receptor
from the endogenous Ig promoter [38] were kindly pro-
vided by Jason Cyster (University of California, San Fran-
cisco). The HEL transgenic mice that expressed secreted
HEL from a metallothionine promoter [38] were also pro-
vided by Jason Cyster. Mice were maintained on a C57BL/
6 background and genotyped by PCR as previously
described [38,53,54]. Eμ-Myc/BCRHEL/HEL transgenic
mice were obtained by crossing Eμ-Myc mice with mice
heterozygous for both BCRHEL and HEL transgenes. All
mice were maintained humanely according to protocols
approved by the Bucknell University Institutional Animal
Care and Use Committee or the UCSF Committee on Ani-
mal Research.
Lymphomas were transplanted by removing the spleen
and three pairs of lymph nodes (inguinal, axillary, and
brachial) from an Eμ-Myc/BCRHEL/HEL transgenic mouse
with externally evident lymphoma. Single cell suspen-
sions were prepared separately from spleens and the
lymph nodes by macerating organs through a 60 μm
mesh screen (Sigma, St. Louis, MO). Red blood cells were
lysed using 17 mM Tris, pH 7.65, 135 mM NH4Cl buffer
and the remaining splenocytes and lymphocytes were
resuspended in complete RPMI media (RPMI 1640 with
L-glutamine, penicillin/streptomycin, non-essential
amino acids, 2 mM HEPES, 2 mM sodium pyruvate, 10
mM  β-mercaptoethanol (all from Invitrogen, Grand
Island, NY), and 10% heat-inactivated fetal bovine serum
(HyClone, Logan, UT)). Cells were counted using a hemo-
cytometer and Trypan blue staining (Sigma). Cells were
washed three times with Hank's Buffered Salt Solution
(HBSS, Invitrogen) and each C57BL/6 recipient mouse
was intravenously injected with 5 × 105 each of cells from
the lymph node and spleen.
Farnesyl Transferase Inhibitors
L-744,832 (BIOMOL, Plymouth Meeting, PA) was dis-
solved in HBSS at 2.5 mg/ml and filtered through a 0.2
μm syringe filter for sterilization. Aliquots were frozen at
-20°C and used within one month. Mice were treated
with L-744,832 by tail vein injection of 0.25 ml once
daily. SCH66336 was generously provided by Robert
Bishop (Schering Plough Research Institute, Kenilworth,
NJ). SCH66336 was dissolved in 20% (w/v) hydroxypro-
pyl-β-cyclodextrin (Sigma) in HBSS at 6.25 mg/ml and fil-
tered through a 0.2 μm syringe filter [19]. Mice were
treated with SCH66336 by oral gavage with 0.25 ml every
10 to 14 hours. SCH66336 aliquots were frozen and
stored at -20°C.
Proliferation Assays
Cell proliferation was measured in culture by labeling
with the dye 5-(6)-carboxyfluorescein diacetate, succinim-
idyl ester (CFSE; Invitrogen). Splenocytes were isolated
from either a BCRHEL transgenic mouse or a moribund Eμ-
Myc/BCRHEL/HEL transgenic mouse as described above. T
cells were depleted using anti-Thy 1.2 paramagnetic beads
as described by the manufacturer (Invitrogen). Cells were
resuspended at 5 × 106 cells/ml in HBSS and labeled for 5
minutes at room temperature by the addition of an equal
volume of 1.0 μM CFSE. The labeling reaction was
quenched by the addition of 2 volumes of fetal bovine
serum, further diluted with complete RPMI, and cells were
then washed three times with complete RPMI. Cells were
then placed in culture at 37°C in 5% CO2 at 5 × 105 cells/
ml in complete RPMI with 2 μg/ml goat anti- mouse IgM,
μ-specific (Jackson Immunoresearch, West Grove, PA), 1
μg/ml anti-mouse CD40 (BD Biosciences, San Diego,
CA), and L-744,832, as indicated. A Becton Dickinson
FACScan flow cytometer was used to measure prolifera-
tion after 3 days. Viable cells were gated based on forward
and side scatter. Between 2500 and 10,000 viable cells
were analyzed for each sample by measuring the CFSE flu-
orescence associated with each cell.
Flow Cytometry
Single cell suspensions from the lymph nodes, spleen, or
thymus of each mouse were prepared as described above.
Cells were resuspended in FACS Buffer and incubated
with anti-CD16/CD32 (BD Biosciences) to block Fc recep-
tors. Cells were then labeled, as indicated, with fluores-
cent antibodies to B220, Thy 1.2, or IgMa  (BD
Biosciences) diluted 1:50 with FACS Buffer. Unbound
antibody was removed by washing with FACS Buffer and
cells were fixed with 1% paraformaldehyde (Sigma) in
HBSS. Viable cells were gated based on forward and side
scatter. For measurement of absolute cell numbers, a
Coulter Counter (Beckman Coulter, Fullerton, CA) was
used to measure cell density and, separately, a sample was
labelled with 7-aminoactinomycin D (7AAD; Invitrogen)
and analyzed by flow cytometry as recommended by the
manufacturer to determine cell viability.
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